Discounted Cash Flow (DCF) Analysis Levered
Blueprint Medicines Corporation (BPMC)
$45.67
+0.02 (+0.04%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 21.43 | 44.52 | 66.51 | 793.74 | 180.08 | 708.27 | 2,785.72 | 10,956.53 | 43,093.21 | 169,490.23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -119.86 | -175.01 | -278.02 | 387.03 | -298.65 | -2,107.27 | -8,288.10 | -32,597.99 | -128,211.42 | -504,269.32 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -15.51 | -12.68 | -14.01 | -3.16 | -261.24 | -378.80 | -1,489.85 | -5,859.73 | -23,046.94 | -90,646.09 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -135.38 | -187.69 | -292.03 | 383.88 | -559.89 | -2,486.06 | -9,777.95 | -38,457.72 | -151,258.36 | -594,915.41 |
Weighted Average Cost Of Capital
| Share price | $ 45.67 |
|---|---|
| Beta | 0.632 |
| Diluted Shares Outstanding | 56.17 |
| Cost of Debt | |
| Tax Rate | -0.47 |
| After-tax Cost of Debt | 5.00% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 6.617 |
| Total Debt | 111.41 |
| Total Equity | 2,565.19 |
| Total Capital | 2,676.60 |
| Debt Weighting | 4.16 |
| Equity Weighting | 95.84 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 21.43 | 44.52 | 66.51 | 793.74 | 180.08 | 708.27 | 2,785.72 | 10,956.53 | 43,093.21 | 169,490.23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -119.86 | -175.01 | -278.02 | 387.03 | -298.65 | -2,107.27 | -8,288.10 | -32,597.99 | -128,211.42 | -504,269.32 |
| Capital Expenditure | -15.51 | -12.68 | -14.01 | -3.16 | -261.24 | -378.80 | -1,489.85 | -5,859.73 | -23,046.94 | -90,646.09 |
| Free Cash Flow | -135.38 | -187.69 | -292.03 | 383.88 | -559.89 | -2,486.06 | -9,777.95 | -38,457.72 | -151,258.36 | -594,915.41 |
| WACC | ||||||||||
| PV LFCF | -2,333.23 | -8,612.73 | -31,792.39 | -117,356.07 | -433,199.50 | |||||
| SUM PV LFCF | -593,293.93 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 6.55 |
| Free cash flow (t + 1) | -606,813.72 |
| Terminal Value | -13,336,565.19 |
| Present Value of Terminal Value | -9,711,285.50 |
Intrinsic Value
| Enterprise Value | -10,304,579.42 |
|---|---|
| Net Debt | -98.54 |
| Equity Value | -10,304,480.88 |
| Shares Outstanding | 56.17 |
| Equity Value Per Share | -183,458.21 |